Inovio Pharmaceuticals Inc [INO] stock is trading at $2.13, up 12.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The INO shares have gain 4.41% over the last week, with a monthly amount glided 12.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inovio Pharmaceuticals Inc [NASDAQ: INO] stock has seen the most recent analyst activity on May 14, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $20. Previously, Oppenheimer upgraded its rating to Outperform on January 25, 2024, and kept the price target unchanged to $4. On November 09, 2022, downgrade downgraded it’s rating to Hold. BofA Securities downgraded its rating to a Underperform but stick to its price target of $2 on November 01, 2022. Oppenheimer downgraded its rating to Perform for this stock on May 11, 2022. In a note dated January 21, 2022, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $8 to $10.
Inovio Pharmaceuticals Inc [INO] stock has fluctuated between $1.74 and $14.75 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. Inovio Pharmaceuticals Inc [NASDAQ: INO] shares were valued at $2.13 at the most recent close of the market. An investor can expect a potential return of 964.32% based on the average INO price forecast.
Analyzing the INO fundamentals
Inovio Pharmaceuticals Inc [NASDAQ:INO] reported sales of 0.20M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -7.67% with Operating Profit Margin at -587.1%, Pretax Profit Margin comes in at -124147.37%, and Net Profit Margin reading is -124147.37%. To continue investigating profitability, this company’s Return on Assets is posted at -235.88, Equity is -264.38 and Total Capital is -1.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9700 points at the first support level, and at 1.8000 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.2100, and for the 2nd resistance point, it is at 2.2900.
Ratios To Look Out For
For context, Inovio Pharmaceuticals Inc’s Current Ratio is 3.88. Further, the Quick Ratio stands at 3.88, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 384.47, the price to book ratio is 0.75.
